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In Brief
The fate of differentiating MSCs
influences the development of obesity
and osteoporosis. Jiang et al. report that
SHP1 controls MSC differentiation
through binding to GSK3b and
suppressing its kinase activity. These
findings reveal a role for SHP1 in
controlling bone and fat mass by
modulating MSC differentiation.
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Osteoblasts and adipocytes are derived from a com-
mon precursor, mesenchymal stem cells (MSCs). Al-
terations in the normal fate of differentiating MSCs
are involved in the development of obesity and oste-
oporosis. Here, we report that viable motheaten
(mev) mice, which are deficient in the SH2-domain-
containing phosphatase-1 (SHP1), develop osteo-
porosis spontaneously. Consistently, MSCs from
mev/mev mice exhibit significantly reduced osteo-
genic potential and greatly increased adipogenic
potential. When MSCs were transplanted into nude
mice, SHP1-deficient MSCs resulted in diminished
bone formation compared with wild-type MSCs.
SHP1 was found to bind to GSK3b and suppress its
kinase activity by dephosphorylating pY216, thus
resulting in b-catenin stabilization. Mice, in which
SHP1 was deleted in MSCs using SHP1fl/flDermo1-
cre, displayed significantly decreased bone mass
and increased adipose tissue. Taken together, these
results suggest a possible role for SHP1 in controlling
tissue homeostasis through modulation of MSC dif-
ferentiation via Wnt signaling regulation.
INTRODUCTION
Mesenchymal stem cells (MSCs) are multipotent and can differ-
entiate into one of several distinct cell lineages under appropriate
conditions, including cartilage-forming chondrocytes (Wu et al.,
2013), bone-forming osteoblasts (Pittenger et al., 1999), and
fat-forming adipocytes, as well as myoblasts, fibroblasts, skel-
etal muscle cells (Moroni and Fornasari, 2013), and neurogenic
lineages (Chamberlain et al., 2007). In addition, several studies
have demonstrated an inverse relationship between adipogene-
sis and osteogenesis (James et al., 2012; Pei and Tontonoz,
2004). An imbalance between adipogenesis and osteogenesis
can lead to various metabolic disorders, including osteoporosis,
osteopetrosis, and obesity (Uccelli et al., 2008).This is an open access article under the CC BY-NMSC differentiation is influenced by several key lineage-
specific transcription factors: C/EBPa, C/EBPb, and C/EBPd
(CCAAT/enhancer-binding proteins) (Darlington et al., 1998), as
well as PPARg (peroxisome proliferation-activated receptor g)
(Zhang et al., 2010), are critical for adipogenesis, while Runx2
(Runt-related transcription factor 2) (Neve et al., 2011) is vital
for osteoblast differentiation. Indeed, several intrinsic signaling
pathways that regulate the expression of lineage-specific tran-
scription factors have been shown to guide MSC differentiation
toward either the osteoblast or adipocyte lineages, including
Wnt/b-catenin signaling. Activation of Wnt/b-catenin signaling
in MSCs favors osteogenesis at the expense of adipogenesis
by modulating the availability of cell-type-specific transcrip-
tion factors (Bennett et al., 2005). Conversely, disruption of
Wnt/b-catenin signaling leads to spontaneous adipogenesis by
MSCs and pre-adipocytes. Wnt/b-catenin signaling regulates
the fate of MSCs by suppressing adipocyte transcription factors,
by stimulating the production of osteoblast transcription factors,
or by both mechanisms (Bennett et al., 2005).
The Src homology protein, SHP1 is predominantly expressed
in hematopoietic cells. SHP1 is traditionally considered to nega-
tively regulate hematopoietic and immune cell function (Shultz
et al., 1997). However, its role in stem cells and some progenitor
cells has only recently been described. SHP1 has been shown to
participate in modulating the stemness of mouse embryonic
stem cells (ESCs) (Cha et al., 2010) and to be involved in neuronal
differentiation (Mizuno et al., 1997). SHP1 activity is completely
absent in the murine motheaten mutation (me/me), whereas
the viable motheaten mutation (mev/mev) retains about 25% of
SHP1 activity. Both of these mutants exhibit classic symptoms
of osteoporosis (Green and Shultz, 1975), including significantly
lower bone marrow density and mineral content in the femur,
compared to wild-type (WT) mice, although the mechanism is
not clear.
It has been suggested that osteoporosis results from
imbalanced differentiation of MSCs into either osteoblasts or
adipocytes. In the present study, we investigated whether
osteoporosis observed in SHP1-deficient mice is due to a cell-
autonomous function of SHP1 in MSC differentiation. We find
that SHP1 promotes osteogenesis and inhibits adipogenesis in
MSCs by modulating Wnt/b-catenin signaling. Importantly, weCell Reports 16, 769–780, July 19, 2016 ª 2016 The Authors. 769
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. mev/mev Mice Develop Osteoporosis with Characteristic Reduced Bone Mass and Lower Bone Density
mCT analysis of tibiae from mev/mev and WT mice (8-week-old males).
(A) Images of trabecular bone of the tibial metaphysis (top) and entire proximal tibia (bottom). Scale bars, 1 mm.
(B) Trabecular bone parameters were quantitated and compared between mev/mev and WT mice. BMD, bone mineral density; BV/TV, bone-volume/tissue-
volume ratio; Tb.N, trabecular number; Tb.Th, trabecular thickness; SMI, structure model index; and Tb.Sp, trabecular separation
Bars represent mean ± SEM (n = 5). *p < 0.05; **p < 0.01; ***p < 0.001.generated SHP1fl/flDermo1-cremice that induce a targeted dele-
tion of SHP1 specifically in MSCs during mesenchymal conden-
sation, which precedes osteogenesis and adipogenesis (Plutzky
et al., 1992). These mice were found to have less bone and more
fat tissue as adults, consistent with the phenotype in SHP1-defi-
cient MSCs. Thus, we present compelling evidence that SHP1
plays an important role in regulating the formation of bone
mass and adipose tissue by MSCs.
RESULTS
mev/mev Mice Exhibit Decreased Bone Mass and Bone
Formation
Previous reports have revealed that mice with partial deficiency
in SHP1 (mev/mev) develop spontaneous osteoporosis, including
lower bone density and bone thickness relative to WTmice (Aoki
et al., 1999). It has also been demonstrated that bone density in
the cortex and spongiosa is lower in mev/mev mice compared
with littermate controls (Umeda et al., 1999). To reproduce these
previous findings, bones from mev/mev and WT male mice were
analyzed bymicro-computed tomography (mCT). mCT analysis of
the cortical bone and trabecular bone in the proximal tibia re-
vealed much lower bone mass in mev/mev mice (Figure 1A).
The trabecular bone-volume/tissue-volume ratio (BV/TV) was
over 50% lower in the mev/mev group, compared with WT con-
trols, and was accompanied by 40% lower bone mineral density
(BMD), 30% less trabecular thickness (Tb.Th), 60% lower
trabecular number (Tb.N), andmore than 50%greater trabecular
separation (Tb.Sp) (Figure 1B). The structure model index (SMI),
which quantifies 3D structure for the relative amounts of plates
and rods (SMI = 0, strong bone; SMI = 3, fragile bone), was about770 Cell Reports 16, 769–780, July 19, 201650% higher (Figure 1B). These results indicate that SHP1 influ-
ences bone formation in vivo.
mev/mev MSCs Promote Less Osteogenesis and More
Adipogenesis in an SHP1 Phosphatase-Dependent
Manner
The diminished levels of bone formation found in mev/mev mice
led us to hypothesize that SHP1 is involved in osteoblast dif-
ferentiation. Osteoblasts are a critical component of bone devel-
opment and maintenance and are known to be derived from
MSCs (Heino and Hentunen, 2008). Therefore, we measured
protein levels of SHP1 in differentiating MSCs isolated from
WT mice, following an established protocol (Ren et al., 2008).
Interestingly, SHP1 levels were observed to increase when
MSCs were subjected to osteogenic differentiation conditions,
while they decreased under adipogenic differentiation condi-
tions (Figure 2A). SHP2, another member of the Src homology
phosphatase family that is also known to regulate adipose tissue
formation (He et al., 2013), was also measured and found to be
expressed at similar levels during both osteogenic and adipo-
genic differentiation (Figure 2A).
To confirm that SHP1 is involved in the process of MSC differ-
entiation, bone marrow MSCs from mev/mev and WT mice were
monitored during culture for their expression of MSC-specific
phenotypic markers (Sung et al., 2008). Immunofluorescence
staining followed by flow-cytometric analysis revealed that
MSCs from both mev/mev and WT mice express Sca1 and
CD44 at similar levels but do not express CD45, CD31, F4/80,
MHC class I, or MHC class II (Figure 2B). Thus, SHP1 had no
obvious effect on the MSC phenotype. When MSCs were
cultured in either osteogenic or adipogenic differentiation
(legend on next page)
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medium, there was a significant difference between mev/mev
and WT MSCs: as predicted, mev/mev MSCs showed dimin-
ished osteogenesis and significantly increased adipogenesis
compared to WT MSCs (Figure 2C). This suggests that SHP1
plays a key role in controlling the fate of differentiating MSCs
in vitro.
Since SHP1, as a protein tyrosine phosphatase, acts by
dephosphorylating its target molecules (Zhang et al., 2000),
we tested whether this enzymatic activity was involved in
SHP1 function during MSC differentiation. When the compound
NSC-87877, an inhibitor of SHP1 phosphatase activity, was
added during WT MSC differentiation under specific conditions,
significantly reduced osteogenesis and enhanced adipogenesis
were observed (Figures 2D and 2E), and these effects were
found to be dose dependent. The expression profiles of key
transcription factors and differentiation markers were analyzed
by real-time PCR after MSCs were subjected to specific differ-
entiation conditions. We found that high concentrations of
the SHP1 inhibitor resulted in significantly lower levels of
Runx2 and associated osteogenic markers, including osteopon-
tin (OPN), collagen 1a (Col1a), and osteocalcin (OCN) in the
MSCs (Figure 2F). Interestingly, even with low concentrations
of SHP1 inhibitor, MSCs displayed strikingly higher levels of
C/EBPa and adipogenic markers, including fatty-acid-binding
protein 4 (FABP4) and adiponectin (Figure 2G). These results
indicate that the phosphatase activity of SHP1 influences MSC
differentiation.
SHP1, but Not SHP2, Is Indispensable for the Normal
Differentiation of MSCs
Because NSC-87887 is not specific for SHP1, it might also
partially inhibit SHP2 activity (Chen et al., 2015). To parse out
their effects, SHP1 and SHP2 were individually knocked down
in WT MSCs; effective knockdown was achieved for both pro-
teins (Figures 3A and 3D). When SHP1-knockdown MSCs were
then cultured in differentiation medium, we found that adipo-
genic differentiation was favored over osteogenic differentiation.
To better quantify this effect, the extent of the differentiated area
was calculated using IMT i-Solution software, and differences in
the percentage of differentiated areas were found to be highly
significant (Figures 3B and 3C). In contrast, SHP2-knockdown
MSCs displayed similar amounts of both osteogenesis and adi-
pogenesis and little difference in calculated areas of differentia-
tion (Figures 3E and 3F). To further verify the role of SHP1, MSCs
were transfected with a constitutive SHP1 expression cassette,Figure 2. SHP1 Deficiency Promotes the Adipogenic, but Not Osteoge
(A) WT MSCs were cultured in adipogenic or osteogenic differentiation medium fo
to WB to detect SHP1 and SHP2. GAPDH, loading control.
(B) After isolation from bone marrow of mev/mev or WT mice and culture for an
markers by immunofluorescence, and analyzed by flow cytometry.
(C)mev/mev andWTMSCswere cultured in adipogenic or osteogenic differentiatio
deposition characteristic of osteogenesis or with oil red O to reveal triglycerides r
(D and E) Graded concentrations of NSC-87877, an SHP1 phosphatase inhibitor
MSCs cultured as in (C) above, and resultant MSCs were stained with alizarin re
(F) WT MSCs were subjected to osteogenic differentiation in the presence of th
collagen 1a (Col1a), and osteocalcin (OCN) on the indicated days were analyzed
(G) WT MSCs were subjected to adipogenic differentiation, and C/EBPa, FABP4
Bars represent means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not signific
772 Cell Reports 16, 769–780, July 19, 2016and SHP1 expression was examined by western blotting (WB)
(Figure 3G). When these SHP1-overexpressing MSCs were
cultured in the respective differentiation media, we observed
enhanced osteogenesis and reduced adipogenesis compared
to WT controls. Software analysis of the extent of differentiated
area confirmed a significant difference (Figures 3H and 3I). These
results indicate that SHP1, but not SHP2, is required for the
normal differentiation of MSCs.
To compare the differentiation capacities in vivo of WT MSCs
and mev/mev MSCs, an MSC implantation system was used.
Carrier particles of hydroxyapatite tricalcium phosphate (HA/
TCP) were mixed with MSCs and then implanted subcutane-
ously under the dorsal skin of nude mice. After 4 or 8 weeks,
the implants were harvested and analyzed by micro-CT and
H&E staining. Micro-CT analysis revealed a dramatically lower
BV/TV in mev/mev MSCs, indicating little bone formation on
the HA/TCP particles in comparison to WT controls (Figure 3J).
Histological analysis revealed consistently that WT MSCs
formed more bone than did mev/mev MSCs, while mev/mev
MSCs formed some adipocytes but no bone mass in the
HA/TCP particles (Figure 3K).When the areas of bone formation
revealed by H&E staining were quantitated using ImageJ soft-
ware, bone formation was found to be much lower in the
mev/mev MSC group than in the WT MSC group at 4 or 8 weeks
(Figure 3L).
SHP1 Modulates the Expression of Transcription
Factors that Regulate Differentiation
Previous studies have shown that Runx2 plays an important role
in osteogenic differentiation (Gersbach et al., 2006) and that
C/EBPa, C/EBPb, and PPARg are key factors driving the adipo-
genic differentiation of MSCs (Cristancho and Lazar, 2011).
Therefore, expression of these transcription factors in WT
MSCs and mev/mev MSCs was assayed by real-time PCR and
WB after up to 9 days in culture. At the mRNA level, mev/mev
MSCs showed markedly lower levels of Runx2 and osteogenic
markers, including OPN, Col1a, and OCN, in both naive and
differentiated states in comparison to WT controls (Figure 4A).
In addition, mev/mev MSCs displayed higher levels of C/EBPa
and adipogenic markers, including FABP4 and adiponectin,
than did WT MSCs (Figure 4B). At the protein level, mev/mev
MSCs had significantly higher levels of C/EBPa and PPARg,
but less Runx2, than didWTMSCs, even when naive (Figure 4C).
However, protein levels of C/EBPb were comparable in WT
MSCs and mev/mev MSCs (Figure 4C).nic, Differentiation of MSCs
r the indicated number of days, and total protein was harvested and subjected
equal number of passages, MSCs were harvested, stained for the indicated
nmedium for several days and then stainedwith alizarin red S to reveal calcium
epresentative of adipogenesis. Scale bars, 500 mm (top) and 100 mm (bottom).
, were added to the osteogenic (D) or adipogenic (E) differentiation medium of
d S (D) or Oil Red O (E). Scale bars, 500 mm in (D) and 100 mm in (E).
e inhibitor NSC-87877, and expression levels of Runx2, osteopontin (OPN),
by real-time PCR.
, and adiponectin were analyzed as in (F).
ant.
Figure 3. SHP1, but Not SHP2, Is Indispensable for Normal Differentiation of MSCs
(A) Efficiency of short hairpin RNA (shRNA)-mediated SHP1 knockdown in WT MSCs was determined by WB. Ctrl, control.
(B) SHP1 knockdown and control MSCswere cultured in osteogenic differentiation medium and then stained with alizarin red S for calcium deposition. The extent
of the stained area was quantitated using IMT i-Solution software. Scale bars, 500 mm.
(C) MSCs, as in (B), were cultured in adipogenic differentiation medium and stained with oil red O for triglycerides. Scale bars, 50 mm.
(D–F) Replication of (A)–(C), except SHP2 was knocked down instead of SHP1. Scale bars, 500 mm in (E) and 50 mm in (F).
(legend continued on next page)
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After SHP1 and SHP2 were individually knocked down in
WT MSCs, protein expression was analyzed by WB. We found
that SHP1-knockdown MSCs expressed more C/EBPa and
PPARg, but similar amounts of Runx2 and C/EBPb, in compari-
son to control MSCs (Figure 4D). In contrast, SHP2-knockdown
MSCs exhibited unchanged levels of C/EBPa, C/EBPb, PPARg,
and Runx2 (Figure 4E). We also found, conversely, that adipo-
genic transcription factors, including C/EBPa, C/EBPb, and
PPARg, were decreased in SHP1-overexpressing MSCs, while
Runx2 was increased, even under naive conditions (Figure 4F).
These results indicate that SHP1 regulates critical transcription
factors during MSC differentiation.
Signaling fromWnt, but Not BMP, Is Involved in Impaired
Osteogenic Differentiation by SHP1-Deficient MSCs
The Wnt and BMP signaling pathways are well known to play
important roles in regulating MSC differentiation (Ling et al.,
2009). Wnt signaling through the canonical b-catenin-dependent
pathways is considered pro-osteogenic and anti-adipogenic
(Case and Rubin, 2010; Glass et al., 2005). To examine whether
SHP1 has a regulatory role in Wnt signaling, the expression
levels of total b-catenin and non-phospho-b-catenin after treat-
ment with Wnt3a were measured in both mev/mev MSCs and
WT MSCs by WB. We observed that both total b-catenin and
non-phospho-b-catenin were dramatically decreased in mev/
mev MSCs compared to WT MSCs (Figure 5A). b-catenin phos-
phorylation ismediated byGSK3b, whose activity is regulated by
site-specific phosphorylation; full activity of GSK-3b generally
requires phosphorylation at tyrosine 216 (Tyr216); conversely,
phosphorylation at serine 9 (Ser9) inhibits GSK-3b activity.
Consistently, we found that GSK3b phosphorylation at Tyr216
was slightly increased, while phosphorylation at Ser9 was de-
tectably decreased in mev/mev MSCs, although total protein
levels of GSK3b were no different from those in controls (Fig-
ure 5B). This indicates that Wnt signaling is diminished in
SHP1-deficient (mev/mev) MSCs.
To further determine how SHP1 regulates the Wnt signaling
pathway, the target molecules of SHP1 had to be defined. To
address this, we examined the interaction between SHP1 and
GSK3b in Wnt3a-treated SHP1-overexpressing MSCs using
immunoprecipitation and WB. First, the amounts of SHP1 and
GSK3bwere determined in whole-protein lysates of SHP1-over-
expressing MSCs before and after Wnt3a treatment, normalized
to GAPDH levels (Figure 5C). Next, immunoprecipitation with
SHP1 revealed that large amounts of GSK3b coprecipitated
with SHP1 in the lysates from SHP1-overexpressing MSCs
both before and after Wnt3a treatment. Additional evidence of(G) WT MSCs were transfected by lentivirus containing an SHP1-expression vec
(H and I) SHP1-overexpressingMSCs and control MSCswere cultured in differenti
red O for adipogenesis. The stained area was quantitated using IMT i-Solution s
(J) MSCs were mixed with HA/TCP, incubated overnight, and the mixture was im
implants were removed, fixed in 4% paraformaldehyde, and analyzed bymicro-CT
implanted into nude mice.
(K) Excised implants were paraffin embedded, sectioned, and stained with H&E,
tween bone (B) and connective tissues (CT), and the arrowheads indicate areas of
Scale bar, 500 mm. W, weeks.
(L) Based on H&E staining, the amount of bone that formed on the HA/TCP parti
Bars represent mean ± SEM (n = 3). **p < 0.01; ***p < 0.001; ns, not significant.
774 Cell Reports 16, 769–780, July 19, 2016the interaction between GSK3b and SHP1 was provided by
GSK3b immunoprecipitation, which resulted in the coprecipita-
tion of SHP1 (Figure 5C). Additionally, small amounts of b-cate-
nin and non-phospho-b-catenin were detected after SHP1
immunoprecipitation (Figures S1A and S1B). SHP1 binding of
b-catenin and non-phospho-b-catenin may result from the bind-
ing of b-catenin to GSK3b. These results indicate that SHP1 reg-
ulates the Wnt signaling pathway by forming a complex with
GSK3b that dephosporylates GSK3b at Tyr216, thereby inhibit-
ing its enzymatic activity. In turn, b-catenin phosphorylation is
decreased, leading to the accumulation and nuclear transloca-
tion of b-catenin, thereby activating gene expression (Figure 5D).
We also examined whether SHP1 is involved in the BMP
signaling pathway. In this pathway, Smad4 interacts with other
phosphorylated Smads to form homomeric or heteromeric com-
plexes, which then translocate to the nucleus, where they regu-
late the transcription of downstream genes (Li, 2008). When the
levels of Smad4 and phosphorylated Smad1/5/9 weremeasured
in MSCs treated with BMP2 or BMP4, no obvious difference
was observed between SHP1-deficient and control MSCs (Fig-
ures S1C and S1D). Therefore, BMP signaling is unlikely to be
involved in the impaired osteogenesis observed in SHP1-defi-
cient MSCs.
Conditional Deletion of SHP1 Interferes with Fat and
Bone Formation
We have shown that inactivation of SHP1 in MSCs in vitro and
in vivo results in greatly reduced osteogenic differentiation and
less bone formation. To further test whether SHP1 plays an
important role in bone formation, we utilized the Cre-Lox recom-
bination system to knock out SHP1 in MSCs in vivo. SHP1fl/fl
mice were crossed with Dermo1-cre mice, in which cre ac-
tivity occurs during mesenchymal condensation and later in
condensed mesenchyme-derived chondrocytes and osteo-
blasts (Li et al., 1995). Therefore, we predicted that SHP1fl/fl
Dermo1-cre mice would lack SHP1 in mesenchymal progen-
itor cells. Indeed, we observed shorter teeth in 3-week-old
SHP1fl/flDermo1-cre mice (Figure 6A). To characterize the
osteoblast differentiation defects in SHP1fl/flDermo1-cre
mice, femurs were analyzed by micro-CT. Insufficient develop-
ment in the bone of the proximal tibia was observed in
SHP1fl/flDermo1-cre mice compared with control SHP1fl/fl mice
(Figure 6B). In addition, trabecular BV/TV was decreased by
more than half, BMD was 20% lower, SMI almost doubled,
Tb.Th and Tb.N were less, and Tb.Sp was increased (Figure 6C).
Microscopic examination of H&E-stained bone sections showed
that fewer trabeculae had developed in SHP1fl/flDermo1-cretor or control vector, and SHP1 expression was measured by WB.
ationmedium and stained respectively with alizarin red S for osteogenesis or oil
oftware. Scale bars, 500 mm in (H) and 100 mm in (I).
planted subcutaneously under the dorsal skin of nude mice. After 8 weeks, the
to determine bone-volume/tissue-volume ratio (BV/TV). PBS, control HA/TCP
and then examined microscopically. Dotted lines delineate the boundary be-
bone or adipose (A) formation. HA/TCP, hydroxyapatite tricalcium phosphate.
cles at 4 and 8 weeks was quantitated using ImageJ software.
Figure 4. SHP1 Regulates Transcription Factors Critical for MSC Differentiation
(A) WT andmev/mevMSCswere subjected to osteogenic differentiation, and expression levels of Runx2, osteopontin (OPN), collagen 1a (Col1a), and osteocalcin
(OCN) on indicated days were analyzed by real-time PCR. d, days.
(B) WT and mev/mev MSCs were subjected to adipogenic differentiation, and C/EBPa, FABP4, and adiponectin were analyzed, as in (A).
(C) Protein levels of Runx2, PPARg, C/EBPa, and C/EBPb were analyzed in naive WT and mev/mev MSCs by WB. Arrows indicate 42 knockdown C/EBPa (top)
and 28 knockdown C/EBPa (bottom).
(D–F) Naive SHP1-knockdown MSCs (D), SHP2-knockdown MSCs (E), and SHP1-overexpressing MSCs (F), as well as respective controls (Ctrl), were analyzed
for expression of Runx2, C/EBPa, C/EBPb, and PPARg using WB.
The differences between the means of WT and mev/mev MSCs at each time point for three independent biological replicates were compared statistically. Bars
represent mean ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001.mice (Figure 6D). Interestingly, however, higher fat-to-body-
weight ratios and more gonadal fat tissue deposition occurred
under a normal diet in both male and female SHP1fl/flDermo1-
cre mice, compared to SHP1fl/fl controls, while the amounts of
subcutaneous fat tissue were comparable (Figure 6E). The
opposite tendencies of subcutaneous and gonadal fat tissue
distribution in SHP1fl/flDermo1-cre mice could be explained by
their different mechanisms of development (Wang et al., 2013,
2015). The fat tissue deposition patterns reveal that SHP1 dele-
tion affects mainly adipocyte differentiation in gonadal fat tis-
sue. Greater fat tissue development in SHP1fl/flDermo1-cre
mice is consistent with the increased adipogenesis seen in
SHP1-deficient MSCs. These results further illustrate that con-
ditional deletion of SHP1 during mesenchymal condensationdelays bone formation, while it enhances gonadal fat tissue
formation.
DISCUSSION
Previous reports have demonstrated that systemic SHP1 defi-
ciency in mice induces significant osteoporosis. However, the
mechanism has not been conclusively determined, nor is it
known whether the observed reduction in osteoblast function
is directly related to a lack of SHP1. Here, we have identified
SHP1 to be a critical regulator of bone mass that functions
by controlling the fate of MSC differentiation, toward either an
osteogenic phenotype or an adipogenic one. The effects of
SHP1 on MSC differentiation are exerted through its regulationCell Reports 16, 769–780, July 19, 2016 775
Figure 5. Wnt Signaling Is Upregulated by SHP1 via Dephosphorylation of GSK3b at Tyr216
(A) WT and mev/mev MSCs were treated with Wnt3a (20 ng/ml) for the indicated times, and non-phospho-b-catenin and total b-catenin expression levels were
evaluated by WB.
(B) WT and mev/mev MSCs were treated as in (A), and expression of GSK3b phosphorylated at either Tyr216 (pGSK3b(Y216)) or at Ser9 (pGSK3b(S9)) and total
GSK3b were determined.
(C) SHP1-overexpressing MSCs were treated with Wnt3a (20 ng/ml) for 30 min, and cell lysates were analyzed for total GSK3b and SHP1 by WB (left) or were
immunoprecipitated (right) with anti-SHP1 (top) or anti-GSK3b (bottom).
(D) Diagrammatic representation of the interaction between SHP1, GSK3b, and other regulatory proteins in Wnt3a signaling (see Discussion for description).of the expression of lineage-specific transcription factors,
including C/EBPs, PPARg, and Runx2, and are linked to upregu-
lation of Wnt signaling.
Osteoblasts and adipocytes are both derived from the same
MSC precursors. Therefore, the effect of SHP1 deficiency on
the differentiation capacity of MSCs was examined in vitro
and ex vivo, using cells from SHP1-deficient mice. We found,
in vitro, that SHP1-deficient MSCs have enhanced adipogenic
differentiation, while osteogenic differentiation is reduced.
In addition, the epitomic bone formation assay demonstrated
that SHP1 is critical for controlling the differentiation of
MSCs. Moreover, adipocyte formation was observed in HA/
TCP particles coated with mev/mev MSCs but not with WT
MSCs. The lineage differentiation of MSCs is controlled by
several specific transcription factors. Adipogenic differentia-
tion is dependent on the C/EBP family and PPARg (Tontonoz
et al., 1994), whereas osteogenic differentiation requires
chiefly Runx2 (Ducy et al., 1997). When expression of these
pivotal transcription factors during MSC differentiation was
analyzed by WB and real-time PCR, the adipogenic transcrip-
tion factors C/EBPa and PPARg were found to be notably776 Cell Reports 16, 769–780, July 19, 2016increased in SHP1-deficient MSCs at both the protein and
mRNA levels.
The expression and activation of specific transcription factors
during MSC differentiation are regulated by several signaling
pathways, the most important being Wnt and BMP signaling.
Most reports have shown that both of these signaling pathways
promote osteogenic differentiation and inhibit adipogenic differ-
entiation. BMP signals control MSC differentiation, mainly by
regulating Runx2 expression through the canonical Smad-
dependent pathways and non-canonical Smad-independent
pathways. BMP family members, such as BMP2, BMP4, and
BMP6, have been show to induce MSC differentiation (Chen
et al., 2012). Deletion of BMP2 or BMP4 in mice leads to defects
in skeletogenesis and a loss of osteogenesis (Bandyopadhyay
et al., 2006). In the present study, however, BMP signals were
found to be unaffected by SHP1. The influences of the canonical
Wnt/b-catenin signaling pathway on osteogenic differentiation
by MSCs are complex and not yet fully elucidated. For the
most part, however, canonical Wnt/b-catenin signaling is
believed to favor osteogenic differentiation by MSCs, rather
than adipogenesis, through inhibition of C/EBP and PPARg
Figure 6. Conditional Deletion of SHP1 Interferes with Fat and Bone Tissue Formation in Mice
Bone formation indicators were compared between SHP1fl/flDermo1-Cre mice and SHP1fl/fl controls.
(A) Differences in tooth length at 3 weeks of age. Scale bars, 5 mm.
(B) mCT images of tibiae from 2-month-old males (representative of five mice) show trabecular bone of the tibial metaphysis (top) and the entire proximal tibia
(bottom). Scale bars, 1 mm.
(C) mCT analysis of tibiae from 2-month-old males (n = 5) revealed differences in trabecular bone parameters: BMD, bone mineral density; BV/TV, bone-volume/
tissue-volume ratio; Tb.N, trabecular number; Tb.Th, trabecular thickness; SMI, structure model index; Tb.Sp, trabecular separation.
(D) Bone was isolated, sectioned, stained with H&E, and observed microscopically. Arrows indicate the developed trabeculae. Scale bars, 500 mm.
(E) Subcutaneous and gonadal fat tissues were isolated from 2-month-old females (top) or males (bottom) (n = 5) and analyzed for total fat ratio and subcutaneous
and gonadal fat weights. sWAT, subcutaneous white adipose tissue; gWAT, gonadal white adipose tissue.
Bars represent mean ± SEM (n = 5); ns, not significant; *p < 0.05; **p < 0.01.expression. For instance, Wnt receptor ligands, such as Wnt6,
Wnt10a, and Wnt10b, are reported to promote osteogenic
MSC differentiation through canonical b-catenin signaling
(Baksh and Tuan, 2007). Studies in whichWnt10b gene dosages
were altered have revealed that Wnt10b is a positive regulator of
bone formation, as it enhances osteoblast differentiation, and it
maintains mesenchymal progenitors, osteoblast progenitors,
or both in adult bone (Bennett et al., 2007; Stevens et al., 2010).
Protein phosphorylation and dephosphorylation at tyrosyl
residues are important regulatory mechanisms that modulate
the activity of proteins involved in the process of cell growth
and differentiation. SHP1 acts as both a positive and a negative
regulator of signal transduction. SHP1 was previously shown
to significantly reduce b-catenin/TCF-dependent transcriptionin intestinal crypt epithelial cells by binding to and dephosphor-
ylating b-catenin (Duchesne et al., 2003). SHP1 has also been
demonstrated to interfere with b-catenin activity by promoting
its degradation in a GSK3b-dependent manner (Simoneau
et al., 2011). Therefore, to verify the role of SHP1, we analyzed
Wnt/b-catenin signaling in SHP1-deficient MSCs derived from
mev/mev mice. When treated with Wnt3a, mev/mev MSCs dis-
played remarkably less non-phospho-b-catenin and more
GSK3b phosphorylation at Tyr216, each of which is involved in
the Wnt signaling pathway. In addition, GSK3b phosphorylation
at Ser9, which is mediated by AKT, was decreased in mev/mev
MSCs, the cause of which remains to be determined. GSK3b is
negatively regulated by PI3K (phosphatidylinositol 3-kinase)-
mediated activation of AKT/PKB (protein kinase B) and by theCell Reports 16, 769–780, July 19, 2016 777
WNT signaling pathway (Clodfelder-Miller et al., 2005). In the
absence of Wnt signals, the scaffolding protein AXIN (Axis inhib-
itor) helps GSK3b to efficiently bind to and phosphorylate b-cat-
enin, thus targeting it for ubiquitination and subsequent proteo-
somal degradation. SHP1 has two tandem SH2 domains at the
N terminus: a single central catalytic domain and a C-terminal
domain. The SH2 domains recruit SHP1 to tyrosine-phosphory-
lated molecules, enabling dephosphorylation to be performed
by the catalytic domain. Using SHP1 immunoprecipitation in
SHP1-overexpressing MSCs, we revealed that SHP1 binds to
GSK3b. Therefore, we propose that SHP1 regulates Wnt/b-cat-
enin signaling by binding to and dephosphorylating GSK3b at
theTyr216 site. Since dephosphorylation inactivates GSK3b,
thereby preventing b-catenin phosphorylation, b-catenin is al-
lowed to accumulate and to translocate to the nucleus, where
it upregulates transcription factor expression.
Both me/me mice and mev/mev mice display bone loss
phenotypes. The development, growth, and repair of the skel-
etal system involve complex processes that are mediated by
multiple cell lineages, including osteoblasts, osteoclasts, and
chondrocytes. In order to further investigate the function of
SHP1 in the skeletal system, we used a conditional gene
deletion approach, utilizing the Cre-LoxP system to generate
SHP1fl/flDermo1-cre mice. Since Dermo1 is expressed during
mesenchymal condensation, which was confirmed by lineage
tracing analysis after crossing with the R26R mouse (Soriano,
1999), SHP1 is deleted in progenitor MSCs that can generate
both osteoblast and chondrocyte lineage cells. This analysis
also showed that both osteoblasts and chondrocytes, derived
from condensed mesenchyme, did indeed express Dermo1-
cre (Liu et al., 2010). In addition, Dermo1-cre has been shown
to be specifically expressed in bone marrow-derived MSCs
(Liu et al., 2010). Significantly, SHP1fl/fl Dermo1-cre mice
showed characteristics of osteoporosis, including fewer
trabeculae and shorter teeth, because of insufficient osteo-
blast formation. In addition, the amount of adipose tissue in
the gonads was increased. These results further illustrate
that SHP1 deficiency in MSCs leads to abnormalities in bone
formation.
In conclusion, this study suggests that SHP1 regulates bone
and fat development in adults by influencing the balance be-
tween osteoblast differentiation and adipocyte differentiation
by MSCs. The tendency toward adipogenic differentiation ap-
pears to be favored in the absence of normal SHP1, suggesting
that SHP1 is a positive regulator of osteogenesis and a negative
regulator of adipogenesis.EXPERIMENTAL PROCEDURES
Mice Generation and Maintenance
Dermo1-cre mice andmev/mev mice (C57BL/6Jbackground) were purchased
from the Jackson Laboratory. SHP1fl/fl mice were kindly supplied by the lab of
W.X. in the Second Military Medical University. Dermo1-cre mice were mated
with SHP1fl/fl mice for at least three generations to generate SHP1fl/fl Dermo1-
cre mice. Female immunocompromised nude mice (BALB/c, nu/nu) were
purchased from the SLAC (Shanghai Laboratory Animal Center) of the Chinese
Academy of Sciences. All procedures were approved by the Institutional
Animal Care and Use Committee of the Institute of Health Sciences, Shanghai
Institutes for Biological Sciences of the Chinese Academy of Sciences.778 Cell Reports 16, 769–780, July 19, 2016Cell Culture
Using our lab-developed protocol, the tibias and femurs of 6- to 10-week-old
WT and age-matchedmev/mev mice were dissected from the surrounding tis-
sues, the bones were cut, and bone marrow cells were collected by flushing
with low-glucose DMEM (Invitrogen). Cell cultures were incubated in a humid-
ified environment containing 5% CO2 at 37
C.
Reagents
Reagents for inducingMSCdifferentiation, including indomethacin, dexameth-
asone, insulin, 3-isobutyl-1-methylxanthine, L-ascorbic acids, and b-glycero-
phosphate, as well as alizarin red S, oil red O, and formaldehyde solution
were purchased from Sigma-Aldrich. Antibodies used in WB were: SHP1
(Abcam); Runx2 (Epitomics); C/EBPa, C/EBPb, PPARg, b-catenin, GSK3b,
non-phospho-b-catenin, pGSK3b, and GAPDH (Cell Signaling Technology).
Differentiation of MSCs
Accordingly, to induce osteogenic differentiation, MSCs were cultured in
high-glucose DMEM supplemented with 10% heat-inactivated FBS, 10 nM
dexamethasone, 100 mM L-ascorbic acid, and 10 mM b-glycerophosphate.
Adipogenic differentiation was induced with high-glucose DMEM containing
0.5mM isobutylmethylxanthin, 60mM indomethacin, 100 nMdexamethasone,
and 10 mg/ml insulin.
Histological Analysis of Differentiated BMSC Cultures
Osteogenesis was evaluated by alizarin red S staining. In brief, the cells were
fixed in cold 70% ethanol for 1 hr, washed twice with H2O, and incubated with
2%alizarin red S (pH = 4.1 to 4.3) for about 15min to reveal calciumdeposition.
Adipogenesis was assessed by oil red O staining to reveal triglycerides: the
cells were fixed in 10% formalin for 1 hr, washed twice with H2O, allowed to
air dry, and then stained with oil red O for about 30 min at room temperature.
Ectopic Bone Formation
Bone-marrow-derived MSCs (2 3 106) were mixed overnight with carrier
particles of ceramic HA-TCP (40 mg; Bio-lu Biomaterials Company), and this
mixture was implanted subcutaneously under the dorsal skin of nude mice.
After 4 or 8 weeks, mice were euthanized, and the harvested particles were
fixed in 4% paraformaldehyde overnight. The particles were analyzed by
mCT and stained with H&E and embedded in paraffin for preparing thin
sections.
Lentivirus Transfection
The lentivirus particles for knocking down SHP1 protein were purchased from
GeneChem. MSCs were infected with the described lentiviral vectors in low-
glucose DMEM supplemented with 10 mg/ml polybrene (GeneChem). After
transfection, MSCs were selected in medium containing puromycin.
Flow-Cytometric Analysis
Cells were harvested after trypsinization and stained with fluorophore-conju-
gated antibodies for 30 min on ice. The cell samples were analyzed using
a BD FACSCalibur flow cytometer (BD Biosciences). FlowJo software was
used for data analysis.
WB
MSCs were scraped off the culture surface and lysed using RIPA lysis buffer
(BeyoTime) on ice. Total protein concentration was measured with the BCA
protein assay kit (Bio-Rad). Protein samples were separated by SDS-PAGE
and transferred to a nitrocellulose membrane, which was then blocked with
5% fat-free milk. Blots were incubated with specific primary antibodies fol-
lowed by anti-rabbit-HRP (horseradish peroxidase), and staining was detected
with the ECL system (Millipore).
Real-Time PCR
Total RNA was extracted using TRIzol (Invitrogen). First-strand cDNA was
synthesized using the cDNA Synthesizing Kit (Takara) according to the manu-
facturer’s instructions. cDNA was applied as a template to determine the
expression of specific genes in real-time PCR with SYBR Green reagent
from Takara. Gene expression was normalized to endogenous b-actin mRNA.
Statistical Analysis
Statistical analysis was performed using Prism 5.0 software (GraphPad).
Unpaired two-tailed Student’s t test was used in all instances, and statistical
significance is reported as follows: ns, not significant; *p < 0.05; **p < 0.01;
***p < 0.001. Bars represent means ± SEM.
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